X

Drug Profile

RP 52028

Alternative Names: PK 11195

Latest Information Update: 24 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator sanofi-aventis
Class Antidepressants; Antiepileptic drugs; Neuroprotectants; Small molecules
Mechanism of Action GABA A receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Anxiety disorders; Cancer; Mood disorders

Most Recent Events

30 Mar 2006 Discontinued - Preclinical for Cancer in United Kingdom (PO)
04 Nov 2004 A preclinical study in multiple myeloma has been added to the Cancer pharmacodynamics section
26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com